久久久久久午夜精品一区二区三区,亚洲一区二区三区高清av桃色,中文字幕大奶美女黄色录像

規(guī)格	庫(kù)存	目錄價(jià)	會(huì)員專享價(jià)	數(shù)量
5 mg	3-5days	￥550.00	登錄后可見(jiàn)	- +
10 mg	3-5days	￥800.00	登錄后可見(jiàn)	- +
25 mg	3-5days	￥1460.00	登錄后可見(jiàn)	- +

規(guī)格

庫(kù)存

目錄價(jià)

會(huì)員專享價(jià)

數(shù)量

5 mg

3-5days

￥550.00

登錄后可見(jiàn)

- +

10 mg

3-5days

￥800.00

登錄后可見(jiàn)

- +

25 mg

3-5days

￥1460.00

登錄后可見(jiàn)

- +

基本信息

英文名稱	trans-4-[4-(4-Amino-7,8-dihydro-5-oxopyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]-cyclohexaneacetic acid
中文名稱	PF-04620110
CAS號(hào)	1109276-89-2
分子式	C21H24N4O4
分子量	396.44
外觀	White to off-white powder
儲(chǔ)存條件	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

產(chǎn)品詳情

PF-04620110 (PF04620110; PF 04620110) is a novel, potent, orally bioactive, and selective diglyceride acyltransferase-1 (DGAT1) inhibitor with the potential to treat type 2 diabetes mellitus. It inhibits DGAT1 with an IC50 of 19 nM. PF-04620110 has been advanced to clinical trials on the basis of the excellent pharmacologic and pharmacokinetic profiles. F-04620110 shows high selectivity versus a broad panel of off-target pharmacologic end points. In vivo DGAT-1 inhibition has been demonstrated through reduction of plasma triglyceride levels in rodents at doses of ≥0.1 mg/kg following a lipid challenge.

相關(guān)文獻(xiàn)

抱歉，暫時(shí)沒(méi)有相關(guān)文獻(xiàn)

相關(guān)產(chǎn)品

抱歉，暫時(shí)沒(méi)有相關(guān)產(chǎn)品

瀏覽記錄

CL2505

PF-04620110

1109276-89-2 98+% 3-5days

￥550.00 5 mg

黄片一区二区三区在线观看-亚洲av综合久久国产激情按摩店-欧美日韩国产长车超污-欧美日韩偷拍精品视频

PF-04620110

trans-4-[4-(4-Amino-7,8-dihydro-5-oxopyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]-cyclohexaneacetic acid

化學(xué)品安全說(shuō)明書(MSDS)